106157-94-2

Usage

Uses

Used in Organic Synthesis:
(E)-1-Dimethylamino-4,4-dimethoxy-pent-1-en-3-one is utilized as a reagent and intermediate in organic synthesis, contributing to the creation of a diverse array of chemical products.
Used in Perfumery and Flavoring Applications:
Leveraging its potent odor, (E)-1-Dimethylamino-4,4-dimethoxy-pent-1-en-3-one is employed in the perfumery industry to enhance the fragrance of personal care products. Its strong scent also makes it a suitable candidate for use in the flavoring of food products, adding depth and character to the taste experience.
Used as a Precursor in Pharmaceutical Synthesis:
(E)-1-Dimethylamino-4,4-dimethoxy-pent-1-en-3-one serves as a crucial precursor in the synthesis of various pharmaceuticals, highlighting its importance in the development of new medicines and therapeutic agents.
Used in the Flavoring Industry:
(E)-1-Dimethylamino-4,4-dimethoxy-pent-1-en-3-one is used as a flavoring agent in the food industry, capitalizing on its strong odor to create unique and appealing tastes in a range of products.
Overall, (E)-1-Dimethylamino-4,4-dimethoxy-pent-1-en-3-one's multifaceted applications across different industries underscore its significance as a versatile and valuable chemical compound.

Upstream product

• 21983-72-2 3,3-dimethoxy-butan-2-one 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 

Downstream Products

• 1009056-19-2 [4-(1,1-dimethoxyethyl)pyrimidin-2-yl]phenylamine 
• 864464-02-8 1-(2-Ethylaminopyrimidin-4-yl)ethanone 
• 521092-13-7 1-(2-cyanobenzyl)-3-(4-fluorophenyl)-4-(2-methylsulfinylpyrimidin-4-yl)-4-imidazolin-2-one 
• 521092-72-8 C₁₆H₁₉FN₄O₅S 
• 521092-71-7 C₁₆H₁₉FN₄O₃S 
• 521092-16-0 1-(4-fluorophenyl)-5-(2-methylsulfinylpyrimidin-4-yl)-4-imidazolin-2-one 
• 521092-46-6 1-(2-methylsulfanylpyrimidin-4-yl)ethanoneoxime tosylate 
• 521087-88-7 1-(2-cyanobenzyl)-3-(4-fluorophenyl)-4-(2-isopropoxypyrimidin-4-yl)-4-imidazolin-2-one 
• 521091-13-4 C₁₆H₁₆FN₅O 
• 521092-64-8 C₁₇H₂₁N₃O₄S 
• 521092-07-9 1-(4-fluorophenyl)-5-(2-methylsulfanylpyrimidin-4-yl)-4-imidazolin-2-one 
• 496863-48-0 1-(2-methylsulfanyl-pyrimidin-4-yl)-ethanone 
• 106157-82-8 4-Acetyl-2-aminopyrimidine 
• 521092-35-3 4-(1,1-dimethoxy-ethyl)-2-methylsulfanyl-pyrimidine 

Relevant academic research and scientific papers

Discovery of anti-cell migration activity of an anti-HIV heterocyclic compound by identification of its binding protein hnRNP M

One compound sometimes shows two biological functions, becoming important aspect of recent drug discovery. This study began with an attempt to confirm the previously reported molecular mechanism of the anti-human immunodeficiency virus (HIV) heterocyclic compound BMMP [2-(benzothiazol-2-ylmethylthio)-4-methylpyrimidine], i.e., induction of abnormal uncoating of the viral core at the post-entry step. Our mechanistic study gave results consistent with this mechanism. We further attempted to find out the molecular target of BMMP by a pulldown approach using previously synthesized biotinylated BMMP (Biotin-BMMP) and successfully identified heterogenous nuclear ribonucleoprotein M (hnRNP M) as a BMMP-binding protein. This protein was found not to be accountable for the anti-HIV activity of BMMP. As hnRNP M has been reported to promote cancer metastasis, we tested this mechanism and found that BMMP suppressed migration of the human lung carcinoma cell line A549 stimulated with transforming growth factor-β (TGF-β). Mechanistic study showed that BMMP suppressed the expression of CD44 mRNA via the regulation of hnRNP M. Furthermore, six new derivatives of BMMP were synthesized, and the patterns of their activities against HIV-1 and cell migration were not uniform, suggesting that the anti-HIV mechanism and the anti-cell migration mechanism of BMMP are independent. Taken together, the anti-cell migration activity of the anti-HIV heterocyclic compound BMMP was newly discovered by identification of its binding protein hnRNP M using a chemical biology approach.

HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA

There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof,wherein the ring containing Q1to Q5, and the groups R1, R2 and R3, have meanings as provided in the description.

AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS

The invention relates to amino-heteroaryl derivatives having the general Formula I or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same, as well as to the use of these derivatives for the treatment of pain, such as neuropathic pain or inflammatory pain.

Heteroarylpyrrolopyridinones active as kinase inhibitors

Compounds represented by formula (I) wherein A, R1, R2, R3, R4, R5 and R6 are as defined in the specification or a pharmaceutically acceptable salt or solvate thereof, compositions thereof,

N-substituted pyrrolopyridinones active as kinase inhibitors

Compounds represented by formula (I) wherein A, R1, R2, R3, R4, R5, and R6 are as defined in the specification, pharmaceutical compositions thereof, and methods of use thereof.

PYRROLOPYRROLONES ACTIVE AS KINASE INHIBITORS

Compounds represented by formula (I) wherein A, R1, R2, R3, and R4 are as defined in the specification, compositions thereof, and methods of use thereof.

Substantially Pure 2-{[2-(2-Methylamino-Pyrimidin-4-YL)-1H-Indole-5-Carbonyl]-Amino}-3-Phenylpyridin-2-YL-Amino)-Propionic Acid as an IkB Kinase Inhibitor

The present invention is directed to the substantially pure compound of formula (A), or pharmaceutically acceptable salt, or solvate of said compound; to a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of formul

PYRIMIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS

Pyrimidylpyrrole derivatives of formula (1) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be

SUBSTANTIALLY PURE 2-{[2-(2-METHYLAMINO-PYRIMIDIN-4-YL)-1H-INDOLE-5-CARBONYL]-AMINO}-3-(PHENYLPYRIDIN-2-YL-AMINO)-PROPIONIC ACID AS AN IKB KINASE INHIBITOR

The present invention is directed to the substantially pure compound of formula (A), or pharmaceutically acceptable salt, or solvate of said compound; to a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of formul

4-IMIDAZOLIN-2-ONE COMPOUNDS

The present invention relates to a compound of the formula [I] : ???wherein G1 is an alkyl which,may be substituted by a halogen atom or an alkoxy, or a group of the formula: ??????wherein ring B is benzene ring which may be substituted, etc.,